Skip to main content
. 2025 May 22;18:2659–2672. doi: 10.2147/IJGM.S524033

Table 1.

Characteristics of Ischemic Stroke Cases and Controls

Variables Initial Cohort Replication Cohort
IS (n=615) Control (n=615) P value IS (n=513) Control (n=525) P value
 Mean age (years) 62.47±9.89 61.53±8.91 0.11 62.32±9.52 61.45±8.76 0.13
 Male/female 408/207 311/304 < 0.001 341/172 322/203 0.093
 Smokers, n (%) 167 (27.2) 73 (11.9) < 0.001 158 (30.8) 91 (17.3) < 0.001
 Hypertension, n (%) 466 (75.8) 199 (32.4) < 0.001 375 (73.1) 194 (37.0) < 0.001
 Diabetes, n (%) 184 (29.9) 51 (8.3) < 0.001 149 (29.0) 65(12.4) < 0.001
 Uric acid (mmol/L) 319.8±88.4 322.1±90.9 0.72 346.54±105.27 338.72±96.35 0.13
 Total cholesterol (mmol/L) 5.07±1.18 5.06±0.99 0.94 4.84±1.13 4.58±1.04 0.088
 Triglycerides (mmol/L) 1.62±1.09 1.42±0.97 < 0.001 1.64±1.03 1.65±1.08 0.88
 HDL-cholesterol (mmol/L) 1.30±0.64 1.41±0.42 < 0.001 1.22±0.75 1.25±0.64 0.49
 LDL-cholesterol (mmol/L) 3.07±1.03 3.01±0.97 0.42 3.18±1.05 3.05±0.98 0.039
 HCY (mmol/L) 11.60±6.06 10.33±3.33 < 0.001 13.25±4.85 12.13±3.56 < 0.001
Antihypertensive Medication 313(50.9) NA 242(47.2) NA
 Antidiabetic Drugs 153(24.9) NA 127(24.8) NA
 Antiplatelet Therapy 609(99.0) NA 508(99.0) NA
 Statins 603(98.0) NA 502(95.6) NA
 Intravenous thrombolysis 22(3.6) NA 17(3.3) NA
 Endovascular treatment 89(14.5) NA 69(13.5) NA

Notes: Continuous data are presented as the mean ± SD, median (range) or n (%). P < 0.05 is indicated in bold font.

Abbreviations: IS, Ischemic stroke; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; HCY, Homocysteine; NA, not available.